Braintree Takes Cypress To Court Over Generic Suprep

Law360, New York (September 12, 2012, 5:04 PM EDT) -- Braintree Laboratories Inc. hit Cypress Pharmaceutical Inc. with a patent suit Tuesday in New York federal court seeking to block Cypress from marketing a generic version of the laxative drug Suprep.

According to the complaint, Cypress notified Braintree on July 31 that it had submitted an abbreviated new drug application to the U.S. Food and Drug Administration for a generic version of Suprep.

Braintree claims that the ANDA filing infringed its patent on the drug and that it is entitled to a court order that the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.